
    
      Patients will receive single-agent treatment with pacritinib 200mg orally twice daily until
      any condition for treatment discontinuation has been met. Patients will be enrolled into one
      of four cohorts: Peripheral T-Cell Lymphoma, not otherwise specified (PTCL, NOS) (cohort 1);
      angioimmunoblastic T-cell lymphoma/follicular helper T-cell (AITL/TFH) PTCL (cohort 2);
      Cutaneous T-Cell Lymphoma (CTCL) - mycosis fungoides (MF) and Sezary syndrome (SS) (cohort
      3); and other eligible, less common PTCL subtypes (cohort 4).
    
  